Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery (NCT02550145) | Clinical Trial Compass
TerminatedPhase 1
Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery
United States10 participantsStarted 2014-02
Plain-language summary
The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions after bariatric surgery in a subset of patients who have severe symptomatic hypoglycemia.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Men and women ages 18-65
* BMI 25-40 with a clinical diagnosis of severe symptomatic hypoglycemia after bariatric surgery
Exclusion Criteria:
* Acute medical illness, such as acute bacterial or viral syndrome, febrile illness, acute abdominal symptoms, orthopedic injury within one week
* History of cardiac failure, renal insufficiency (estimated Crcl\<30cc/min), hepatic insufficiency, chronic obstructive pulmonary disease, anemia (Hct\<30%), or uncontrolled hypertension (SBP\>160 or DBP\>100)
* Pregnancy
* Use of medications that affect glucose metabolism
* Fasting glucose \>150 or HbA1c\>7.5 on Metformin
* Women of childbearing potential (will have a pregnancy test, in addition use of abstinence for at least one month prior to study or use two types of contraceptives, hormonal implant or Depo Provera)
* Active, uncontrolled psychiatric disease
* Participating in other studies or have received investigational medications within the past month or 5 half-lives of the drug, whichever is longer.